More than half of patients with low- or intermediate-risk prostate cancer who underwent treatment with Erleada had no evidence of residual disease after 90 days, a recent study showed. Adding 90 days ...

HRQOL was similar across treatment groups, with no significant differences in FACT-P scores at 25 weeks. APA-alone group showed a more favorable time to deterioration in emotional well-being compared ...

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ -- ...